Vivos Therapeutics, Inc. (VVOS) Institutional Ownership

Ownership Summary

According to SEC filings for the period ending December 2025, Vivos Therapeutics, Inc. (NASDAQ:VVOS) is held by 19 institutional firms.

• The percentage of Vivos Therapeutics owned by institutions changed from 6.2% in September 2025 to 6.0% in December 2025, marking a slight down trend.
• On a quarter-over-quarter basis, institutional holdings shifted by 89.44%, with a year-over-year a decrease of 5.00% in the count of filers.
• The latest 13F cycle for Vivos Therapeutics reveals that of 19 total investors, 7 funds grew their exposure, whereas 3 reduced theirs and 9 made no changes.
• Collectively, institutional investors increased their stake in Vivos Therapeutics to 658.10K shares as of December 2025, a change that is up by 310.71K shares quarter on quarter and up 191.32K shares year over year.
• With 304.16K shares, VANGUARD GROUP INC commands the largest institutional position in Vivos Therapeutics as of December 31, 2025, equating to 2.76% of the company.
• Among the most significant buyers of Vivos Therapeutics during December 2025 were VANGUARD GROUP INC (212.70K), DRW Securities, LLC (74.44K), Acorn Wealth Advisors, LLC (14.78K), UBS Group AG (12.57K), GEODE CAPITAL MANAGEMENT, LLC (3.00K).
• Leading sellers of Vivos Therapeutics stock in December 2025 included OSAIC HOLDINGS, INC. (5.41K), MORGAN STANLEY (1.06K), COMMONWEALTH EQUITY SERVICES, LLC (500).
• The top 10 institutional holders of Vivos Therapeutics for the quarter ending December 2025 included VANGUARD GROUP INC (304.16K), DRW Securities, LLC (115.91K), GEODE CAPITAL MANAGEMENT, LLC (56.29K), B. Riley Wealth Advisors, Inc. (43.53K), COMMONWEALTH EQUITY SERVICES, LLC (40.50K), BlackRock, Inc. (27.82K), STATE STREET CORP (24.92K), Acorn Wealth Advisors, LLC (14.78K), UBS Group AG (12.68K), NORTHERN TRUST CORP (12.51K).